Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Journal of Clinical Oncology

• Publication date

  1996-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1996.14.6.1913PMID 8656260
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amifostine improves the antileukemic therapeutic index of mafosfamide : implications for bone marrow purging

  1995cited by this paper
• 577 Amifostine reduces cumulative cisplatin nephrotoxicity

  1995cited by this paper
• Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.

  1995cited by this paper
• 500 Amifostine (AMI) selectively protects against cumulative toxicities of cyclophosphamide (C) and cisplatin (P)

  1995cited by this paper
• Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.

  1994cited by this paper
• Cancer statistics, 1994

  1994cited by this paper
• A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.

  1994cited by this paper
• Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.

  1994cited by this paper
• Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

  1993cited by this paper
• Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.

  1993cited by this paper
• Cancer statistics, 1993

  1993cited by this paper
• Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.

  1992cited by this paper
• A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study.

  1991cited by this paper
• Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B.

  1990cited by this paper
• Promotion of cystine uptake, increase of glutathione biosynthesis, and modulation of glutathione status by S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR-2721) in Chinese hamster cells.

  1989cited by this paper
• Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.

  1989cited by this paper
• Cisplatin neuropathy. Risk factors, prognosis, and protection by WR‐2721

  1988cited by this paper
• WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.

  1987cited by this paper
• A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma.

  1986cited by this paper
• A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.

  1986cited by this paper
• Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer.

  1986cited by this paper
• Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment.

  1985cited by this paper
• Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721.

  1982cited by this paper
• Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study.

  1982cited by this paper
• The modification of melphalan toxicity in tumor bearing mice by S‐2‐(3‐aminopropylamino)‐ethylphosphorothioic acid (WR2721)

  1982cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper
• Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721.

  1981cited by this paper
• Biological Characteristics of Some Improved Radioprotectors

  1980cited by this paper
• Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide.

  1980cited by this paper
• Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties.

  1980cited by this paper
• Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine.

  1979cited by this paper
• Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine.

  1979cited by this paper
• Prediction of Creatinine Clearance from Serum Creatinine

  1976cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper
• Differential chemoprotection of normal and malignant tissues.

  1969cited by this paper

• Nanomedicine Innovations for Lung Cancer Diagnosis and Therapy

  2024cites this paper
• The Neuroprotective Effect of Amitriptyline on Radiation-Induced Impairment of Hippocampal Neurogenesis

  2019cites this paper
• Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents.

  2019cites this paper
• Clinical Status and Optimal Use of Amifostine Review

  2017cites this paper
• The effect of Amifostine, in chemotherapy, radiotherapy, as potential Cytoprotectant, and Immunomodulatory, in Cancer and Autoimmunity Treatment and Prevention

  2017cites this paper
• Antioxidants and Inhibition of Cisplatin-Induced Kidney Injury: Role of Mitochondria

  2012cites this paper
• Prospective Single-Arm Study of Radioprotection by Amifostine in High Dose Radioactive Iodine Therapy for Thyroid Cancer

  2012cites this paper
• Amifostine

  2012cites this paper
• Cytoprotective effects of amifostine in the treatment of childhood malignancies

  2009cites this paper
• A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.

  2009cites this paper
• Prevention and treatment of regimen-related mucosal toxicity.

  2008cites this paper
• MOLECULAR MECHANISM AND BIOLOGICAL EFFECTS

  2008cites this paper
• Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1.

  2007cites this paper
• Cytoprotective agents used in the treatment of patients with cancer.

  2007cites this paper
• Antimetastatic effect of a lipophilic ascorbic acid derivative with antioxidation through inhibition of tumor invasion

  2006cites this paper
• Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53

  2006cites this paper
• Cost-Effectiveness Analysis of Amifostine (Ethyol©) in Patients with Non-Small Cell Lung Cancer

  2006cites this paper
• Established and emerging uses of cytoprotection in head and neck cancer.

  2006cites this paper
• Prospective Single Arm Study of Radioprotection by Amifostine in High Dose Radioiodine Therapy for Thyroid Cancer

  2005cites this paper
• Therapieoptimierungsverfahren bei Patienten mit rezidivierten oder progredienten Keimzelltumoren Hochdosischemotherapie, Residualtumorresektion und Supportivtherapie

  2004cites this paper
• Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.

  2004cites this paper
• Targeting the checkpoint kinases: chemosensitization versus chemoprotection

  2004cites this paper
• Amifostine for children with medulloblastoma treated with cisplatin‐based chemotherapy

  2004cites this paper
• Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia

  2003cites this paper
• Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer

  2003cites this paper
• Randomized Phase III Trial of Postoperative Radiochemotherapy ± Amifostine in Head and Neck Cancer

  2003cites this paper
• Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity.

  2003cites this paper
• The Cytoprotective Aminothiol WR1065 Activates p53 through a Non-genotoxic Signaling Pathway Involving c-Jun N-terminal Kinase*

  2003cites this paper
• Amifostine as chemoprotectant in metastatic breast cancer patients treated with doxorubicin.

  2003cites this paper
• Induction of caspase 3 and modulation of some apoptotic genes in human acute promyelocytic leukemia HL-60 cells by carboplatin with amifostine.

  2003cites this paper
• Improved tolerability of amifostine with rapid infusion and optimal patient preparation.

  2002cites this paper
• A Pilot Study on Feasibility and Efficacy of Amifostine Preceding High-dose Melphalan with Autologous Stem Cell Support in Myeloma Patients

  2002cites this paper
• Amifostine in clinical oncology: current use and future applications

  2002cites this paper
• Influence of amifostine on reconstitution of lymphocyte subpopulations after conventional- and high-dose chemotherapy in patients with germ cell tumor

  2002cites this paper
• Amifostine protects against early but not late toxic effects of doxorubicin in infant rats.

  2001cites this paper
• Perspectives in cancer chemotherapy.

  2001cites this paper
• Manganese superoxide dismutase‐plasmid/liposome (MnSOD‐PL) administration protects mice from esophagitis associated with fractionated radiation

  2001cites this paper
• Sensitizers and protectors of radiation and chemotherapy.

  2001cites this paper
• Anticancer Drug—Induced Kidney Disorders

  2001cites this paper
• Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors.

  2001cites this paper
• Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study

  2001cites this paper
• Amifostine (Ethyol) as modulator of hepatic and biliary toxicity from intraarterial hepatic chemoembolization: results of a phase I study.

  2001cites this paper
• Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.

  2001cites this paper
• A Phase II trial of cisplatin plus WR‐2721 (amifostine) for metastatic breast carcinoma

  2001cites this paper
• Brain Tumors Carboplatin-induced Hearing Loss in Patients with Malignant Delayed Sodium Thiosulfate as an Otoprotectant Against Updated

  2001cites this paper
• Amifostine: chemotherapeutic and radiotherapeutic protective effects

  2001cites this paper
• The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway

  2000cites this paper
• Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.

  2000cites this paper
• The influence of amifostine used alone or in combination with 2-chlorodeoxyadenosine on normal and chronic myelogenous leukemia granulocyte-macrophage progenitor cells in vitro.

  2000cites this paper
• A Randomized Trial Comparing the Nephrotoxicity of Cisplatin/Ifosfamide-Based Combination Chemotherapy with or without Amifostine in Patients with Solid Tumors

  2000cites this paper
• Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II study.

  2000cites this paper
• The potential role of amifostine in the treatment of non small cell lung cancer.

  2000cites this paper
• Cytoprotection as a New Supportive Strategy in the Treatment of Solid Tumors

  2000cites this paper
• New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study.

  2000cites this paper
• Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.

  2000cites this paper
• The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors

  2000cites this paper
• Clinical status and optimal use of amifostine.

  1999cites this paper
• Amifostine as protective agent in cisplatin-based chemotherapy of advanced bladder cancer

  1999cites this paper
• The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects

  1999cites this paper
• The potential of amifostine: from cytoprotectant to therapeutic agent.

  1999cites this paper
• Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-kappaB/Rel transcription factors.

  1999cites this paper
• Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine.

  1999cites this paper
• [Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].

  1999cites this paper
• Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review).

  1999cites this paper
• Neurologic protection by amifostine.

  1999cites this paper
• A Risk-Benefit Assessment of Amifostine in Cytoprotection

  1999cites this paper
• Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.

  1999cites this paper
• A new administration schedule for amifostine as a radioprotector in cancer therapy.

  1999cites this paper
• Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.

  1999cites this paper
• Amifostine modulation of bleomycin-induced lung injury in rodents.

  1999cites this paper
• Cytoprotection in the treatment of pediatric cancer: review of current strategies in adults and their application to children.

  1999cites this paper
• Future directions in non-small cell lung cancer.

  1999cites this paper
• Amifostine and combined-modality therapeutic approaches.

  1999cites this paper
• Chemotherapy Side Effects and Their Management

  1999cites this paper
• Chemoprotectants

  1999cites this paper
• Clinical status and optimal use of amifostine.

  1999cites this paper
• Indications for use of amifostine.

  1998cites this paper
• Strategies for using cytoprotective agents to improve outcomes associated with cancer chemotherapy

  1998cites this paper
• Paclitaxel, cisplatin, etoposide combination chemotherapy: a multifractionated bolus dose schedule for non-small cell lung cancer.

  1998cites this paper
• Reducing the toxicity of anticancer therapy: new strategies.

  1998cites this paper
• New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors.

  1998cites this paper
• Prophylaxe und Behandlung spezieller Nebenwirkungen von Zytostatika

  1998cites this paper
• DIFFERENTIATION THERAPY OF MYELODYSPLASTIC SYNDROMES: FACT OR FICTION?

  1998cites this paper
• Lung Cancer: Therapeutic Modalities and Cytoprotection

  1998cites this paper
• Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma.

  1997cites this paper
• Current role of protective agents in cancer treatment.

  1997cites this paper
• Amifostine for protection from antineoplastic drug toxicity.

  1997cites this paper
• Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer.

  1997cites this paper
• Free radicals and antioxidants in chemotherapy-induced toxicity.

  1997cites this paper
• A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection

  1997cites this paper
• Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.

  1997cites this paper
• Amifostin

  1997cites this paper
• Amifostine. A novel cytoprotective agent.

  1997cites this paper
• Free radicals and antioxidants in chemotherapyinduced toxicity

  1997cites this paper
• Chemotherapy for advanced non-small cell lung cancer.

  1997cites this paper
• Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.

  1997cites this paper
• Pharmacology of cancer chemotherapy in the older person.

  1997cites this paper
• High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer.

  1996cites this paper
• [Amifostine: current and future applications in cytoprotection].

  1996cites this paper